Medindia
Medindia LOGIN REGISTER
Advertisement

ALEVE-D(R) Sinus & Cold Offers Option for the More Than 50% of Consumers Not Satisfied with Current Sinus Medication

Tuesday, October 23, 2007 General News
Advertisement
MORRISTOWN, N.J., Oct. 22 Bayer Consumer Care announcesthe availability of the newly-named ALEVE-D(R) Sinus and Cold (formerly ALEVECold and Sinus), combining a long-lasting nasal decongestant with thepain-relieving power of ALEVE (naproxen sodium) for all-day relief frommultiple sinus and pain symptoms.
Advertisement

The combination of ingredients in ALEVE-D address consumer concerns asidentified in a recent survey of adults who suffer from sinus symptoms. Morethan half of those polled (56 percent) say they are not completely satisfiedwith their current sinus medication, reporting that their medication does notlast long enough (65 percent) and that they need more than one product tocompletely relieve their symptoms (62 percent). The symptoms most commonlyexperienced by those surveyed are stuffy nose or nasal congestion (89percent), sinus congestion (78 percent) and headache (73 percent).
Advertisement

The active ingredients in ALEVE-D, pseudoephedrine (PSE) and naproxensodium combine to provide 12 hours of relief from symptoms including sinuspressure, headache, and nasal and sinus congestion.

"Consumers rely on the ALEVE family of products for long-lasting relief,"said Jay Kolpon, Vice President, Marketing and New Business Development, BayerConsumer Care. "With ALEVE-D, we are offering consumers the power of ALEVEcombined with the proven effectiveness of pseudoephedrine in one pill thatprovides 12 hours of relief from sinus and pain symptoms."

Each ALEVE-D caplet contains naproxen sodium (220mg) and PSE HCL (120mg).Adults and children 12 years and older may take one caplet every eight to 12hours while symptoms last, and should not exceed two capsules in a 24-hourperiod. ALEVE-D is available exclusively behind the pharmacy counter withouta prescription.

For more information, visit www.AleveD.com.

About ALEVE and ALEVE-D

Since its introduction as an OTC product in June 1994, ALEVE has been usedby millions of Americans as a safe and effective pain reliever for more than adecade. With the convenience of all day relief with just one pill, ALEVE-Dtemporarily relieves cold, sinus and flu symptoms including sinus pressure,minor body aches and pains, headache, nasal and sinus congestion (promotessinus drainage and restores freer breathing through the nose) and fever.Always read and follow label instructions.

About Bayer Consumer Care

The Consumer Care Division of Bayer HealthCare LLC, is headquartered inMorristown, N.J. Bayer's Consumer Care Division is among the largestmarketers of over-the-counter medications and nutritional supplements in theworld. Some of the most trusted and recognizable brands in the world todaycome from the Bayer portfolio of products. These include Bayer(R) Aspirin,ALEVE(R), Alka-Seltzer Plus(R), Bactine(R), RID(R), Phillips'(R) Milk ofMagnesia, Midol(R), Alka-Seltzer(R), One-A-Day(R) multivitamins andFlintstones(TM) vitamins.

Bayer Corporation, headquartered in Pittsburgh, is a subsidiary of BayerAG, an international health care, nutrition and innovative materials groupbased in Leverkusen, Germany. In North America, Bayer had 2006 net sales of7.8 billion euros and employed 17,200 at year end. Bayer's three subgroups,Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, improvepeople's lives through a broad range of essential products that help preventand treat diseases; protect crops and enhance yields; and advance automobilesafety and durability.

About the Survey

This survey was conducted by The Segmentation Company, a division ofYankelovich. These results were based on a telephone survey conducted betweenAugust 9-12, 2007, among a sample of 675 Americans age 18 and older who sufferfrom sinus symptoms. For results based on the total sample, the margin oferror is plus or minus 3.8 percentage points. For results based on smallersub samples, the margin of
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close